ABSTRACT VORELOXIN COMBINED WITH CYTARABINE HAS ADDITIVE OR SYNERGISTIC ACTIVITY IN S PHASE
The current analysis was performed in support of a Phase 1b/2 clinical study (SPO-0012) of voreloxin in combination with cytarabine in relapsed or refractory AML, and to investigate the feasibility for combining voreloxin with other agents currently in clinical use for the treatment of AML. The cytotoxicity of voreloxin in combination with cytarabine was evaluated in 3 acute leukemic cell lines (HL-60 acute promyelocytic (APL), MV4-11 Flt-3 ITD positive AML and CCRF-CEM acute lymphoblastic leukemia (ALL)). The cytotoxicity of voreloxin in combination with the nucleoside analog hypomethylating agents azacitidine, decitabine (pyrimidine analogs), and clofarabine (purine analog) was also studied in the HL-60 APL cell line. Cytotoxicity was assessed by proliferation inhibition.
The combined activity of voreloxin and cytarabine was evaluated using the combination index (CI) analysis method, in which each drug is serially diluted based on either 10X or 1X single agent IC50 values. The combination was synergistic in the AML cell lines MV4-11 and HL-60, as demonstrated by a leftward shift in the voreloxin IC50 curves and calculated CI less than 0.85. In the ALL cell line CCRF-CEM, an additive increase in cytotoxicity was observed with CI of ≤ 0.99.
Voreloxin in combination with azacitidine, decitabine or clofarabine was evaluated after simultaneous or sequential addition of the drugs. The combinations were analyzed by: 1) serial-dilution of voreloxin combined with a fixed dose (IC10 ) of the second compound, and 2) fixed dose (IC10 ) of voreloxin combined with a serial dilution of the second compound. No significant change in activity was observed when compared with the single-agent activity of each compound. Sequential dosing of the agents did not alter the cytotoxicity of the reagents in combination.
These data support the ongoing phase 1b/2 clinical study of voreloxin in combination with cytarabine in relapsed or refractory AML and demonstrate the feasibility for combining voreloxin with other DNA damaging agents currently in clinical use for the treatment of AML. 
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Each data point represents an independent experiment.
• Voreloxin is a first-in-class anticancer quinolone derivative with Phase 2 clinical proof-of-concept in AML and ovarian cancer.
• Voreloxin combined simultaneously with cytarabine is synergistic or additive in acute leukemia cell lines.
-These data support the ongoing clinical study of voreloxin in combination with cytarabine in relapsed/refractory AML.
• These data support the feasibility for further investigation of voreloxin in combination with other DNA damaging agents that are currently in use for the treatment of AML -Voreloxin activity combined with nucleoside analogs azacitidine, decitabine or clofarabine is additive in the HL-60 acute promyelocytic cell line. -Sequential combination of voreloxin with nucleoside analogs retained additivity.
• Clinical development of voreloxin continues with ongoing studies in AML and platinum-resistant ovarian cancer.
Clinical development updates will be presented at 
METHOD RESULTS AND DATA ANALYSIS
Example data set: azacitidine added after 24 hr voreloxin pre-treatment
COMBINATION INDEX (CI) ANALYSIS
METHOD VORELOXIN IS AN ANTICANCER QUINOLONE DERIVATIVE (AQD)
Voreloxin is a naphthyridine analog, closely related in structure to the quinolone antibacterials.
• Voreloxin intercalates DNA and poisons topoisomerase II, causing site-selective DNA damage and apoptosis.
• Site selective DNA damage is analogous to the quinolones in bacterial DNA.
• Broad therapeutic index • Evades common drug resistance pathways of P-gp mediated efflux and p53 mutation.
• Anthracyclines intercalate DNA and poison topoisomerase II, but are structurally unrelated to the quinolones.
• Voreloxin is active in anthracycline-resistant settings.
• Low potential for cardio/organ toxicity due to more chemically stable structure and minimal production of reactive oxygen species (ROS).
• Low risk of CYP450-mediated drug-drug interaction. Voreloxin is structurally unrelated to the anthracyclines, but has a similar mechanism of action
